This database contains 457 studies, archived under the term: "drug therapy"
Click here to filter this large number of results.
A multicenter, open-label, 24-week follow-up study for efficacy on cognitive function of donepezil in Binswanger-type subcortical vascular dementia
Jay Cheol Kwon,,
Eung Gyu Kim,,
Jae Woo Kim,,
Oh Dae Kwon,,
Bong Goo Yoo,,
Hyon Ah Yi,,
Nack Cheon Choi,,
Seon Young Ahn,,
Byung Hwa Lee,,
Myong Jin Kang,,
Dae Seob Choi,
Objectives: To evaluate the efficacy and tolerability of donepezil in patients with Binswanger type subcortical vascular dementia.; Methods: Patients (n = 34, mean age = 71.8 + 7.12) with Binswanger type subcortical vascular dementia from 8 multicenter, according to clinical and neuroradiological working criteria, were selected to receive donepezil 5 mg/day (n = 2) or […]
Phase II crossover trial of varenicline in mild-to-moderate Alzheimer’s disease
Kim, Seong Yoon,
Choi, Seong Hye,
Rollema, Hans,
Schwam, Elias M.,
McRae, Tom,
Dubrava, Sarah,
Jacobsen, Janice
Background: Evidence supports a role of α4β2 receptors in Alzheimer’s disease (AD).; Methods: This Korean, multicenter, double-blind, two-period (6 weeks each), crossover study randomized participants to the order in which they received varenicline (1 mg twice daily) and placebo. Assessments included AD Assessment Scale-Cognitive Subscale (ADAS-Cog) 75, Neuropsychiatric Inventory (NPI), adverse events (AEs) and Columbia-Suicide […]
Demonstration of safety in Alzheimer’s patients for intervention with an anti-hypertensive drug Nilvadipine: results from a 6-week open label study
Kennelly, S. P.,
Abdullah, L.,
Paris, D.,
Parish, J.,
Mathura, V.,
Mullan, M.,
Crawford, F.,
Lawlor, B. A.,
Kenny, R. A.
Background: Nilvadipine may lower rates of conversion from mild-cognitive impairment to Alzheimer’s disease (AD), in hypertensive patients. However, it remains to be determined whether treatment with nilvadipine is safe in AD patients, given the higher incidence of orthostatic hypotension (OH) in this population, who may be more likely to suffer from symptoms associated with the […]
Clinically meaningful treatment responses after switching to galantamine and with addition of memantine in patients with Alzheimer’s disease receiving donepezil
Kano, Osamu,
Ito, Hirono,
Takazawa, Takanori,
Kawase, Yuji,
Murata, Kiyoko,
Iwamoto, Konosuke,
Nagaoka, Tetsuro,
Hirayama, Takehisa,
Miura, Ken,
Nagata, Riya,
Kiyozuka, Tetsuhito,
Aoyagi, Jo,
Sato, Ryuta,
Eguchi, Teruo,
Ikeda, Ken,
Iwasaki, Yasuo
Clinical trials have shown the benefits of acetylcholinesterase inhibitors, such as donepezil and galantamine, and an N-methyl-d-aspartate receptor antagonist, memantine, in patients with Alzheimer’s disease (AD). However, little is known regarding the effects of switching from donepezil 5 mg/day to galantamine 16 or 24 mg/day, or regarding the effects of adding memantine to established therapy […]
Efficacy of memantine in PDD and DLB: an extension study including washout and open-label treatment
Johansson, C.,
Ballard, C.,
Hansson, O.,
Palmqvist, S.,
Minthon, L.,
Aarsland, D.,
Londos, E.
Objective: This 30-week extension trial was a continuation of the first double-blind randomized controlled trial (RCT) to study memantine in dementia with Lewy bodies (DLB) and Parkinson’s disease dementia (PDD). The objective was to evaluate the presence of recurrence of symptoms upon drug withdrawal. Furthermore, the aim was to explore washout dynamics in order to […]
The effects of oxytocin on social cognition and behaviour in frontotemporal dementia
Jesso, S.,
Morlog, D.,
Ross, S.,
Pell, M. D.,
Pasternak, S. H.,
Mitchell, D. G. V.,
Kertesz, A.,
Finger, E. C.
Patients with behavioural variant frontotemporal dementia demonstrate abnormalities in behaviour and social cognition, including deficits in emotion recognition. Recent studies suggest that the neuropeptide oxytocin is an important mediator of social behaviour, enhancing prosocial behaviours and some aspects of emotion recognition across species. The objective of this study was to assess the effects of a […]
Omega-3 fatty acid supplementation effects on weight and appetite in patients with Alzheimer’s disease: the omega-3 Alzheimer’s disease study
Faxén Irving, Gerd,
Freund-Levi, Yvonne,
Eriksdotter-Jönhagen, Maria,
Basun, Hans,
Brismar, Kerstin,
Hjorth, Erik,
Palmblad, Jan,
Vessby, Bengt,
Vedin, Inger,
Wahlund, Lars-Olof,
Cederholm, Tommy
Objectives: To study the effects of omega (Omega)-3 fatty acid (FA) supplements on weight and appetite in patients with mild to moderate Alzheimer’s disease (AD) in relation to inflammatory biomarkers and apolipoprotein E epsilon4 (APOEepsilon4).; Design: Randomized, double-blind, placebo-controlled trial.; Setting: Specialist memory clinics in the Stockholm catchment area.; Participants: Two hundred four patients (aged […]